You are here: Industry Insights > Akcea

News List

Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen pharmaceutical-business-review
November 06, 2020
Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics, Inc., announced that Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol ...
NICE u-turn sees Akcea's Waylivra win NHS funding pharmatimes
September 21, 2020
Akcea Therapeutics UK's Waylivra (volanesorsen), the first and only therapy for Familial Chylomicronaemia Syndrome (FCS), will be funded on the NHS after all, following a u-turn by the National Institute for Health and Care Excellence (NICE).
Ionis to Acquire Outstanding Shares of Akcea for $500M contractpharma
September 01, 2020
Ionis will benefit from Akcea's pipeline and commercial products, and further strengthens financial position to support future investments.
Akcea Appoints SVP, Global Medical Affairs contractpharma
July 21, 2020
Cristophe Hotermans brings 12 years’ experience in the biotechnology industry.
Akcea, Ionis Announce Initiation of Trial for Amyloid Cardiomyopathy Treatment americanpharmaceuticalreview
January 16, 2020
Akcea Therapeutics and Ionis Pharmaceuticals announced the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy).
Akcea Therapeutics Announces New Board of Directors Appointments americanpharmaceuticalreview
December 23, 2019
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, announced the appointments of Lynne Parshall, J.D., as chair of the Akcea Board of Directors and Barbara Yanni ...
Akcea Announces CEO Transition, Elects Two New Board Members americanpharmaceuticalreview
September 24, 2019
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, announced its board of directors has appointed Damien McDevitt, Ph.D., a member of its board of directors ...
Rejected by the FDA, Ionis and Akcea's Waylivra finds new life with EU approval fiercepharma
May 09, 2019
With its chances for an FDA approval dead in the water, Ionis and Akcea’s ultrarare lipid disorder treatment Waylivra seemed doomed. Fortunately, the drug found new life in Europe.
‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR pharmatimes
April 18, 2019
The National Institute of Health and Care Excellence (NICE) has issued draft highly specialised technologies guidance……
NICE rejects Alnylam and Akcea’s amyloidosis drugs pharmaphorum
December 14, 2018
NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance.

Previous page 1 2 Next page